JPH07504882A - 皮膚透過において制御された時間変化で薬剤を経皮的に投与するためのデバイス - Google Patents
皮膚透過において制御された時間変化で薬剤を経皮的に投与するためのデバイスInfo
- Publication number
- JPH07504882A JPH07504882A JP5507214A JP50721493A JPH07504882A JP H07504882 A JPH07504882 A JP H07504882A JP 5507214 A JP5507214 A JP 5507214A JP 50721493 A JP50721493 A JP 50721493A JP H07504882 A JPH07504882 A JP H07504882A
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- drug
- reservoir
- skin
- solvents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00553—Plasters form or structure with detachable parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00604—Multilayer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00646—Medication patches, e.g. transcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (14)
- 1.投与期間にわたり無傷の皮膚領域を通じて薬剤を投与するデバイスであって 、該領域を通じての薬剤の透過量が、制御された様式で時間的に変化し、以下を 包含するデバイス:(a)あらかじめ決定された重量比で第1の溶媒と第2の溶 媒とを含有する溶媒混合物に溶かされた該薬剤を含有するリザーバーであって、 少なくとも一方の溶媒は皮膚透過増強剤であり、そして該透過量が該リザーバー 中の第1の溶媒の第2の溶媒に対する重量比の関数である、リザーバー;(b) 該投与期間中に、リザーバーから該第1および第2の溶媒のうちの一方が他方に 関して、制御された異なる移動を達成するための手段であって、それによって該 リザーバー中の該第1の溶媒の該第2の溶媒に対する重量比が制御された様式で 変化し、そして該透過量が制御された様式で変化する、手段;および (c)薬剤および溶媒移動関係における該デバイスを該皮膚領域に保持するため の手段。
- 2.前記第1の溶媒が揮発性であり、第2の溶媒が不揮発性であり、そして、( b)項が、リザーバーを覆う支持体層を有し、該層が該第1の溶媒を透過し、投 与期間中において溶媒がリザーバーから蒸発する速度を調節する、請求項1に記 載のデバイス。
- 3.(b)項が該リザーバーの下に存在する膜を有し、該膜が前記第1および第 2の溶媒に対して変化する度合をもって透過性があり、そして、該第1および第 2の溶媒がリザーバーから皮膚へ拡散する速度を調節する、請求項1に記載のデ バイス。
- 4.(b)項がリザーバーの下に存在する膜を有し、該膜がさらに、前記第1お よび第2の溶媒に対して変化する度合をもって透過性があり、そして、該第1お よび第2の溶媒がリザーバーから皮膚へ拡散する速度を調節する、請求項2に記 載のデバイス。
- 5.前記あらかじめ決定された重量比が、前記第1および第2の溶媒の皮膚への 分配がほぼ最大となるような重量比である、請求項1に記載のデバイス。
- 6.前記第1の溶媒がエタノールであり、第2の溶媒がプロピレングリコールモ ノラウレートであり、そして、あらかじめ決定された重量比がおよそ4:1であ る、請求項1に記載のデバイス。
- 7.前記リザーバーが、前記第1および第2の溶媒中の薬剤の溶液が含まれる封 じ込められた空間の形状である、請求項1に記載のデバイス。
- 8.前記リザーバーが、前記第1および第2の溶媒中の薬剤の溶液が分散された ポリマーマトリックスの形態である、請求項1に記載のデバイス。
- 9.前記ポリマーマトリックスが、疎水性のポリマーと親水性のポリマーとの混 合物を含有する、請求項3に記載のデバイス。
- 10.前記第1および第2の溶媒中の薬剤の溶液が親水性のポリマーと合わされ ている、請求項9に記載のデバイス。
- 11.(c)項が感圧性粘着剤のインライン層である、請求項1に記載のデバイ ス。
- 12.前記膜が感圧性の粘着性を有し、そして、前記皮膚領域に薬剤と溶媒の移 動関係におけるデバイスを維持するための手段を構成する、請求項3に記載のデ バイス。
- 13.投与期間にわたり表皮領域を通じて経皮的に薬剤を投与する方法であって 、該領域を通じた薬剤の透過量が、制御された様式で時間的に変化し、以下の工 程を包含する、方法(a)あらかじめ決定された重量比で第1の溶媒と第2の溶 媒とを含有する溶媒混合物に溶かされた薬剤の処方物を付与する工程であって、 該溶媒の少なくとも一つは皮膚透過増強剤であり、そして、該透過量が該第1の 溶媒の該第2の溶媒に対する重量比の関数である、工程;および(b)投与期間 中に、一方の溶媒が他方に関して、制御された異なる移動を達成する工程であっ て、それによって処方物中の該第1の溶媒の該第2の溶媒に対する重量比が制御 された様式で変化し、従って該透過量が制御された様式で変化する、工程。
- 14.経皮的に薬剤を投与する方法であって、皮膚を通じた薬剤の透過量につい ての初期パルスがあり、続いて皮膚を通じた薬剤の十分に低い透過量があり、以 下の工程を包含する方法: (a)該薬剤および揮発性溶媒および不揮発性溶媒の処方物を皮膚に付与する工 程であって、少なくとも一方の溶媒が皮膚透過増強剤であり、該処方物が揮発性 溶媒を透過し得る支持体によりカバーされている、工程; (b)該支持体を介して該処方物から該揮発性溶媒を蒸発させる工程であって、 それによりパルスの規模と持続が、とりわけ支持体の揮発性溶媒に対する透過性 によって決定される、工程。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/775,638 US5352456A (en) | 1991-10-10 | 1991-10-10 | Device for administering drug transdermally which provides an initial pulse of drug |
PCT/US1992/008631 WO1993006803A1 (en) | 1991-10-10 | 1992-10-09 | Device for administering drug transdermally with a controlled temporal change in skin flux |
US775638 | 1996-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07504882A true JPH07504882A (ja) | 1995-06-01 |
JP3011459B2 JP3011459B2 (ja) | 2000-02-21 |
Family
ID=25105020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5507214A Expired - Lifetime JP3011459B2 (ja) | 1991-10-10 | 1992-10-09 | 皮膚透過において制御された時間変化で薬剤を経皮的に投与するためのデバイス |
Country Status (10)
Country | Link |
---|---|
US (2) | US5352456A (ja) |
EP (1) | EP0608357B1 (ja) |
JP (1) | JP3011459B2 (ja) |
AT (1) | ATE161411T1 (ja) |
AU (1) | AU657582B2 (ja) |
CA (1) | CA2120508A1 (ja) |
DE (1) | DE69223801T2 (ja) |
FI (1) | FI941569A (ja) |
NO (1) | NO308395B1 (ja) |
WO (1) | WO1993006803A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530902A (ja) * | 2007-06-22 | 2010-09-16 | サイエル ファーマ,インコーポレイティド | 流涎症治療のためのグリコピロレートを含む経皮送達システム |
JP2016532641A (ja) * | 2013-10-07 | 2016-10-20 | テイコク ファーマ ユーエスエー インコーポレーテッド | デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物 |
WO2017164084A1 (ja) * | 2016-03-24 | 2017-09-28 | 株式会社メドレックス | 誤用防止特性を有する貼付製剤 |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
FR2735027B1 (fr) * | 1995-06-07 | 1998-01-09 | Alza Corp | Compositions de renforcateurs de permeation d'agents a travers la peau, comprenant de l'acetate de lauryle et un monoglyceride |
US20020114827A1 (en) * | 1995-07-28 | 2002-08-22 | Jie Zhang | Methods and apparatus for improved administration of analgesics |
US20040265353A1 (en) * | 1995-07-28 | 2004-12-30 | Zars, Inc. | Systems and methods for treating panic attacks |
DE19546024C2 (de) * | 1995-12-09 | 1998-09-10 | Lohmann Therapie Syst Lts | Transdermale pharmazeutische Zubereitung und deren Herstellung |
US5686096A (en) * | 1995-12-22 | 1997-11-11 | Becton Dickinson And Company | Medical device for the protection of a catheter penetration site |
US5730721A (en) | 1996-01-25 | 1998-03-24 | Vesture Corporation | Medical applicator and method |
US5837289A (en) * | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
AU758193B2 (en) * | 1996-09-17 | 2003-03-20 | U.D. Testing, Inc. | Therepeutic agent with quantitative consumption marker |
AU736645B2 (en) * | 1996-09-17 | 2001-08-02 | U.D. Testing, Inc. | Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption |
US6660295B2 (en) | 1997-09-30 | 2003-12-09 | Alza Corporation | Transdermal drug delivery device package with improved drug stability |
WO1999032153A1 (en) | 1997-12-22 | 1999-07-01 | Alza Corporation | Monoglyceride and ethyl palmitate permeation enhancer compositions |
US5900249A (en) * | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US6136801A (en) * | 1998-12-24 | 2000-10-24 | U. D. Testing, Inc. | Therapeutic agent with quantitative consumption marker |
KR20010036685A (ko) | 1999-10-11 | 2001-05-07 | 김윤 | 펜타닐을 함유하는 매트릭스형 경피투여제 |
US20010033858A1 (en) * | 2000-02-29 | 2001-10-25 | Jie Zhang | Transdermal drug patch |
US7713546B1 (en) * | 2001-04-03 | 2010-05-11 | Soft Gel Technologies, Inc. | Corosolic acid formulation and its application for weight-loss management and blood sugar balance |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
DE10102817B4 (de) * | 2001-01-23 | 2006-01-12 | Lts Lohmann Therapie-Systeme Ag | Vorrichtung und Verfahren zur Hitzepulsgestützten transdermalen Applikation von Wirkstoffen |
WO2003003957A1 (en) * | 2001-07-06 | 2003-01-16 | Lavipharm Laboratories Inc. | Quick dissolving oral mucosal drug delivery device with moisture barrier coating |
NZ531789A (en) * | 2001-08-17 | 2006-01-27 | Lavipharm Lab Inc | A medical device from which analgesic drugs are delivered from a drug reservoir controlled by plasticizers and adhesive matrix material |
KR100844312B1 (ko) * | 2001-09-06 | 2008-07-07 | 노사케미컬(주) | 펜타닐 경피 투여 제제 |
CN1317948C (zh) * | 2002-01-31 | 2007-05-30 | 病害控制织物有限公司 | 叠层杀虫剂分配物 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1546184A4 (en) * | 2002-07-16 | 2006-08-23 | Univ South Florida | HUMAN IMMUNOSUPPRESSIVE PROTEIN |
SI1534286T1 (sl) | 2002-07-29 | 2010-04-30 | Rigel Pharmaceuticals Inc | Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami |
CN100336569C (zh) * | 2002-10-20 | 2007-09-12 | 浙江大学 | 经皮给药电穿孔系统 |
US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
EP2027854A1 (en) | 2002-11-18 | 2009-02-25 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
US20070031463A1 (en) * | 2003-02-26 | 2007-02-08 | Spiros Fotinos | Methods and devices for releasing volatile substances |
WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
ATE506953T1 (de) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
DE602004024228D1 (de) | 2003-10-27 | 2009-12-31 | Univ Basel | Transdermales arzneimittelabgabesystem |
US7105263B2 (en) * | 2003-12-30 | 2006-09-12 | Samsung Electronics Company | Dry toner comprising encapsulated pigment, methods and uses |
US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US20060051435A1 (en) * | 2004-08-19 | 2006-03-09 | Udell Ronald G | Nutritional supplement for body fat reduction |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
ES2527340T3 (es) | 2005-05-24 | 2015-01-22 | Chrono Therapeutics, Inc. | Dispositivo portátil de administración de fármaco que incluye un elemento de dosificación o administración desmontable y reemplazable |
US8372040B2 (en) * | 2005-05-24 | 2013-02-12 | Chrono Therapeutics, Inc. | Portable drug delivery device including a detachable and replaceable administration or dosing element |
US20070104805A1 (en) * | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
AT502717A1 (de) * | 2005-11-09 | 2007-05-15 | Omnica Gmbh | Pharmazeutische verwendung einer verbindung |
GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
WO2007092350A1 (en) * | 2006-02-02 | 2007-08-16 | H.B. Fuller Licensing & Financing, Inc. | Wound care articles, drug delivery systems and methods of using the same |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2007100870A2 (en) | 2006-02-28 | 2007-09-07 | The Trustees Of Columbia University In The City Of New York | Methods for compact aggregation of dermal cells |
AT503521A1 (de) * | 2006-05-05 | 2007-11-15 | Omnica Gmbh | Verwendung eines extraktes von kiwi-frucht |
WO2008008281A2 (en) | 2006-07-07 | 2008-01-17 | Proteus Biomedical, Inc. | Smart parenteral administration system |
JP2008044926A (ja) * | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
ES2380551T3 (es) | 2006-11-21 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos |
US7820207B2 (en) * | 2007-03-15 | 2010-10-26 | Omnica Gmbh | Stabilized anthocyanin compositions |
US8623429B2 (en) | 2007-03-15 | 2014-01-07 | Omnica Gmbh | Stabilized anthocyanin compositions |
US20080293644A1 (en) * | 2007-04-27 | 2008-11-27 | Thomas Eidenberger | Guava extract |
WO2009027850A2 (en) * | 2007-06-06 | 2009-03-05 | Multi-Tech Specialty Chemicals Co., Ltd. | Process for the preparation of xanthophyll crystals |
EP2211974A4 (en) | 2007-10-25 | 2013-02-27 | Proteus Digital Health Inc | INFORMATION SYSTEM FOR LIQUID FLOW CHANNEL |
US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
WO2009089380A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of Columbia University In The City Of New York | Methods for p2ry5 mediated regulation of hair growth and mutants thereof |
EP2278879B1 (en) * | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
WO2010033626A1 (en) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Compounds, compositions and methods comprising imidazole and triazole derivatives |
JP5656834B2 (ja) * | 2008-08-22 | 2015-01-21 | サノフイ | 肥満細胞トリプターゼインヒビターとしての[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−[7−フルオロ−1−(2−メトキシ−エチル)−4−トリフルオロメトキシ−1h−インドール−3−イル]−メタノン |
AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
JP5815411B2 (ja) | 2008-12-30 | 2015-11-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ピリミジンジアミンキナーゼ阻害剤 |
SG2014005318A (en) | 2009-01-23 | 2014-03-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
WO2010091198A1 (en) | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
JP5753844B2 (ja) | 2009-07-08 | 2015-07-22 | ダーミラ(カナダ),インコーポレーテッド | 皮膚疾患または病変の治療に有用なtofa類似体 |
US20110034415A1 (en) * | 2009-07-20 | 2011-02-10 | Thomas Eidenberger | Walnut extracts for nutraceutical applications |
FR2955324A1 (fr) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
US20110144200A1 (en) | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
EP2519520A1 (en) | 2009-12-23 | 2012-11-07 | Sanofi | [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(1h-pyrrolopyridinyl)-methanone derivatives as tryptase inhibitors |
MY155980A (en) | 2009-12-23 | 2015-12-31 | Sanofi Sa | Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
KR20120114368A (ko) | 2010-02-01 | 2012-10-16 | 프로테우스 디지털 헬스, 인코포레이티드 | 양 손목을 이용한 데이터 수집 시스템 |
WO2011094606A2 (en) | 2010-02-01 | 2011-08-04 | Proteus Biomedical, Inc. | Data gathering system |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
US20110288093A1 (en) | 2010-04-20 | 2011-11-24 | Institute For Oneworld Health | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives |
US20110288103A1 (en) | 2010-04-20 | 2011-11-24 | Institute For Oneworld Health | Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives |
EP2563771B1 (en) | 2010-04-24 | 2015-11-25 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
US20120208855A1 (en) | 2010-07-12 | 2012-08-16 | Sanofi | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
KR101937495B1 (ko) | 2010-07-28 | 2019-01-10 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
CA2816088A1 (en) | 2010-10-28 | 2012-05-03 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
DK2635299T3 (da) | 2010-11-02 | 2019-10-21 | Univ Columbia | Fremgangsmåder til behandling af hårtabsforstyrrelser |
EP3483147A1 (en) | 2010-11-13 | 2019-05-15 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
BR112013014484A2 (pt) | 2010-12-13 | 2016-07-19 | Viamet Pharmaceuticals Inc | compostos inibidores de metaloenzimas |
CA2828360A1 (en) | 2011-02-25 | 2012-08-30 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Chrysophaentin analogs that inhibit ftsz protein |
KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
EP3067350B1 (en) | 2011-06-19 | 2018-06-13 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
JP6122846B2 (ja) | 2011-06-19 | 2017-04-26 | ヴィアメット ファーマスーティカルズ,インコーポレイテッド | 金属酵素阻害剤化合物 |
EA201490052A1 (ru) | 2011-06-23 | 2014-04-30 | Вайамет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
WO2013019169A1 (en) | 2011-08-01 | 2013-02-07 | Institute For Oneworld Health | Phosphate prodrugs |
EP3072555B1 (en) | 2011-09-02 | 2020-03-25 | The Trustees of Columbia University in the City of New York | Mk2/3 inhibitors to treat metabolic disturbances of obesity |
CA2858681C (en) | 2011-12-11 | 2021-07-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
EA026209B1 (ru) | 2012-01-20 | 2017-03-31 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
NZ629898A (en) | 2012-03-23 | 2016-04-29 | Oxigene Inc | Compositions and methods for inhibition of cathepsins |
SI2830662T1 (sl) | 2012-03-29 | 2019-01-31 | The Trustees Of Columbia University In The City Of New York | Postopki zdravljenja motenj izgube las |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
AU2014209263B2 (en) | 2013-01-25 | 2018-11-01 | Rigel Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory bowel diseases |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
EP3842419B1 (en) | 2013-02-28 | 2024-04-03 | Journey Medical Corporation | Method of making threo glycopyrrolate tosylate |
KR20150129847A (ko) | 2013-03-15 | 2015-11-20 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 융합 단백질 및 이들의 방법 |
TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
TWI629067B (zh) | 2013-10-07 | 2018-07-11 | 美商帝國製藥美國股份有限公司 | 用於經皮輸送非鎮靜量右美托咪啶之方法及組成物 |
JP6469587B2 (ja) | 2013-12-18 | 2019-02-13 | 丸石製薬株式会社 | 含水型貼付剤 |
WO2015134920A1 (en) | 2014-03-07 | 2015-09-11 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
WO2015143184A1 (en) | 2014-03-19 | 2015-09-24 | Viamet Pharmaceuticals, Inc. | Antifungal compound process |
EP3925979A3 (en) | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
DK3271347T3 (da) | 2015-03-19 | 2022-07-18 | Mycovia Pharmaceuticals Inc | Antifungale forbindelser og fremstillingsfremgangsmåder |
WO2017023941A1 (en) | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
EA036098B1 (ru) | 2015-09-18 | 2020-09-28 | ВиПиЭс-3, ИНК. | Способ получения противогрибковых соединений |
US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
CA3006469C (en) | 2015-12-30 | 2023-01-10 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
US20170273974A1 (en) | 2016-03-24 | 2017-09-28 | Medrx Co., Ltd | Patch preparations with misuse prevention features |
ES2940911T3 (es) | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
EP3478091B1 (en) | 2016-06-29 | 2024-03-20 | Halo Life Science, LLC | Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline |
CN110234637B (zh) | 2016-10-26 | 2022-11-01 | 里格尔药品股份有限公司 | 用作irak抑制剂的吡唑酰胺化合物 |
CN110099899B (zh) | 2016-10-26 | 2024-01-02 | 里格尔药品股份有限公司 | 用作irak抑制剂的噁唑衍生物及其制备方法 |
EP3562306A4 (en) | 2016-12-29 | 2020-06-24 | Selenity Therapeutics (Bermuda), Ltd. | METALLOENZYME INHIBITOR COMPOUNDS |
FI3562487T3 (fi) | 2016-12-29 | 2023-12-14 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloentsyymi-inhibiittoriyhdisteitä |
CN110337290A (zh) | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
JP7167069B2 (ja) | 2017-06-29 | 2022-11-08 | ライジェル ファーマシューティカルズ, インコーポレイテッド | キナーゼ阻害剤ならびに作製および使用のための方法 |
IL278417B2 (en) | 2018-05-03 | 2024-05-01 | Rigel Pharmaceuticals Inc | RIP1 inhibitory compounds and methods for their preparation and use |
FI3788045T3 (fi) | 2018-05-03 | 2023-06-28 | Rigel Pharmaceuticals Inc | RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
BR112020026672A2 (pt) | 2018-06-27 | 2021-03-30 | Bioxcel Therapeutics, Inc. | Formulações de filme contendo dexmedetomidina e métodos para produzi-las |
WO2020092845A1 (en) | 2018-11-01 | 2020-05-07 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
TWI772807B (zh) | 2019-05-27 | 2022-08-01 | 日商救急藥品工業股份有限公司 | 外用製劑 |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
CN114698370A (zh) | 2019-08-08 | 2022-07-01 | 里格尔药品股份有限公司 | 用于治疗细胞因子释放综合征的化合物和方法 |
MX2022001890A (es) | 2019-08-14 | 2022-04-26 | Rigel Pharmaceuticals Inc | Metodo para bloquear o mejorar el sindrome de liberacion de citocinas. |
MX2022002292A (es) | 2019-08-30 | 2022-06-02 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones. |
TW202122397A (zh) | 2019-09-06 | 2021-06-16 | 美商雷傑製藥公司 | Rip1抑制性化合物及用於製備和使用其之方法 |
PE20221628A1 (es) | 2019-09-06 | 2022-10-19 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos |
CN115298184A (zh) | 2019-11-07 | 2022-11-04 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
US20220288047A1 (en) | 2021-03-03 | 2022-09-15 | Rigel Pharmaceuticals, Inc. | Method for treating a disease or condition using a pyrazole compound or formulation thereof |
TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
US20230303555A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
US20230312568A1 (en) | 2022-03-31 | 2023-10-05 | Rigel Pharmaceuticals, Inc. | Tricyclic irak inhibitors |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060084A (en) * | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4698062A (en) * | 1985-10-30 | 1987-10-06 | Alza Corporation | Medical device for pulsatile transdermal delivery of biologically active agents |
US4927632A (en) * | 1986-06-26 | 1990-05-22 | Alza Corporation | Selective pulsed drug delivery system |
US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US4956181A (en) * | 1987-05-08 | 1990-09-11 | Eastman Kodak | Nitrate therapy for angina pectoris |
US4764379A (en) * | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
US5300291A (en) * | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
US4814168A (en) * | 1988-03-04 | 1989-03-21 | Noven Pharmaceuticals, Inc. | Transdermal multipolymer drug delivery system |
US5352456A (en) * | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
-
1991
- 1991-10-10 US US07/775,638 patent/US5352456A/en not_active Expired - Lifetime
-
1992
- 1992-10-09 US US08/211,029 patent/US5820875A/en not_active Expired - Lifetime
- 1992-10-09 AT AT92922512T patent/ATE161411T1/de not_active IP Right Cessation
- 1992-10-09 DE DE69223801T patent/DE69223801T2/de not_active Expired - Lifetime
- 1992-10-09 AU AU27961/92A patent/AU657582B2/en not_active Expired
- 1992-10-09 WO PCT/US1992/008631 patent/WO1993006803A1/en active IP Right Grant
- 1992-10-09 EP EP92922512A patent/EP0608357B1/en not_active Expired - Lifetime
- 1992-10-09 CA CA002120508A patent/CA2120508A1/en not_active Abandoned
- 1992-10-09 JP JP5507214A patent/JP3011459B2/ja not_active Expired - Lifetime
-
1994
- 1994-04-06 FI FI941569A patent/FI941569A/fi unknown
- 1994-04-07 NO NO941255A patent/NO308395B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530902A (ja) * | 2007-06-22 | 2010-09-16 | サイエル ファーマ,インコーポレイティド | 流涎症治療のためのグリコピロレートを含む経皮送達システム |
JP2016532641A (ja) * | 2013-10-07 | 2016-10-20 | テイコク ファーマ ユーエスエー インコーポレーテッド | デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物 |
WO2017164084A1 (ja) * | 2016-03-24 | 2017-09-28 | 株式会社メドレックス | 誤用防止特性を有する貼付製剤 |
Also Published As
Publication number | Publication date |
---|---|
NO941255L (no) | 1994-04-07 |
DE69223801D1 (de) | 1998-02-05 |
CA2120508A1 (en) | 1993-04-15 |
ATE161411T1 (de) | 1998-01-15 |
FI941569A (fi) | 1994-06-06 |
EP0608357A1 (en) | 1994-08-03 |
DE69223801T2 (de) | 1998-07-30 |
FI941569A0 (fi) | 1994-04-06 |
US5820875A (en) | 1998-10-13 |
NO941255D0 (no) | 1994-04-07 |
AU2796192A (en) | 1993-05-03 |
JP3011459B2 (ja) | 2000-02-21 |
WO1993006803A1 (en) | 1993-04-15 |
EP0608357A4 (en) | 1994-08-17 |
AU657582B2 (en) | 1995-03-16 |
EP0608357B1 (en) | 1997-12-29 |
US5352456A (en) | 1994-10-04 |
NO308395B1 (no) | 2000-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07504882A (ja) | 皮膚透過において制御された時間変化で薬剤を経皮的に投与するためのデバイス | |
US5006342A (en) | Resilient transdermal drug delivery device | |
US5614211A (en) | Oxybutynin transdermal device having decreased delamination | |
KR930001082B1 (ko) | 피부 또는 점막에 유효약제의 투여장치 | |
US4906463A (en) | Transdermal drug-delivery composition | |
US4908027A (en) | Subsaturated transdermal therapeutic system having improved release characteristics | |
US5603947A (en) | Method and device for providing nicotine replacement therapy transdermally/transbuccally | |
JP2749832B2 (ja) | 改良された薬物経皮供給デバイス | |
FI103478B (fi) | Menetelmä transdermaalisen terapeuttisen järjestelmän valmistamiseksi, jossa vaikuttavan aineen virtausta on suurennettu | |
US6007837A (en) | Drug delivery devices and process of manufacture | |
US9050247B2 (en) | Pharmaceutical composition for external use | |
LT3753B (en) | Device for administering dexmedetomidine transdermally | |
US4910205A (en) | Transdermal delivery of loratadine | |
PT89706B (pt) | Metodo e dispositivo para a impressao de farmacos de libertacao transdermico | |
JPS63119421A (ja) | 速度コントロール接着剤を有する改良された経皮投与デバイス | |
JPH044295B2 (ja) | ||
WO1994021262A1 (en) | Device for the transdermal administration of alprazolam | |
KR100281235B1 (ko) | 활성성분으로서 17-β-에스트라디올 무수물을 함유하는 경피치료계 | |
JPS6393714A (ja) | 経皮吸収貼付剤 | |
JP2538372B2 (ja) | 活性物質の作用を遅延及び制御する形の皮膚経由又は粘膜経由投与のための治療薬 | |
KR100624500B1 (ko) | 레리세트론 전달용 경피치료시스템 | |
CA2259407C (en) | Drug delivery devices and process of manufacture | |
JPH02149514A (ja) | 医薬部材 | |
KR100439659B1 (ko) | 툴로부테롤을 함유하는 경피흡수용 패취제 | |
JP2781016B2 (ja) | 経皮吸収製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071210 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081210 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091210 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101210 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101210 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111210 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111210 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121210 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term |